Article Text

Download PDFPDF
Vaginal brachytherapy management of stage I and II endometrial cancer
  1. Anne Sophie V M van den Heerik1,
  2. Nanda Horeweg1,
  3. Carien L Creutzberg1 and
  4. Remi A Nout2
  1. 1 Department of Radiation Oncology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands
  2. 2 Department of Radiation Oncology, Erasmus Medical Center - Cancer Institute, Rotterdam, Zuid-Holland, The Netherlands
  1. Correspondence to Dr Remi A Nout, Department of Radiotherapy, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands; r.nout{at}erasmusmc.nl

Abstract

Adjuvant radiotherapy is an important component of post-operative therapy for patients with early-stage endometrial cancer. In the past decades, many trials have been conducted to determine the optimal adjuvant treatment strategy, pelvic external beam radiotherapy or vaginal brachytherapy. As a result, vaginal brachytherapy became the treatment of choice for patients with early-stage endometrial cancer at high-intermediate risk, based on clinicopathological risk factors. Vaginal brachytherapy maximizes local control and has only mild side effects with limited impact on quality of life, in comparison with pelvic external beam radiotherapy. The most frequently used treatment schedule is the one which was used in the PORTEC-2 trial (21 Gy in three fractions specified at 5 mm depth) and, whenever available, image-guided brachytherapy should be used. However, the most convenient and effective treatment schedule remains to be established. More recently, the discovery and integration of four molecular classes in the risk assessment of endometrial cancer patients has created new opportunities to prevent over- and undertreatment. The 2021 endometrial cancer guideline of the European Society of Gynaecological Oncology (ESGO), European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) now proposes an integrated risk stratification, in which both clinicopathologic and molecular factors are combined, to direct adjuvant therapy. This rationale is now investigated in multiple prospective trials. This review provides an overview of the rationale and currently recommended and new strategies for vaginal brachytherapy in patients with stage I and II endometrial cancer.

  • radiation oncology
  • radiotherapy
  • endometrial neoplasms
  • endometrium
  • uterine neoplasms

Statistics from Altmetric.com

Footnotes

  • Twitter @NandaHoreweg

  • Contributors ASVMH conducted primary research and drafted the original manuscript, all authors contributed in reviewing, editing, and approving the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests ASVMH reports a research grant from the Dutch Cancer Society, during the conduct of the PORTEC-4a study, outside the submitted work. NH reports grants from Dutch Cancer Society and Varian outside the submitted work. CLC report grants from Varian, non-financial support from Elekta, other from Merck, outside the submitted work; and Dutch Cancer Society clinical trial grants. RAN reports grants from Dutch Cancer Society, Dutch Research Council, Elekta, Varian, Accuray, outside the submitted work.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.